Randomized Phase II Study Comparing Efficacy and Safety of Combination-Therapy Trastuzumab and Docetaxel vs. Sequential Therapy of Trastuzumab Followed by Docetaxel Alone at Progression As First-Line Chemotherapy in Patients with HER2+ Metastatic Breast Cancer: HERTAX Trial

Publication | Open Access

DOI Full Paper Access

Citations

References

2011

Year

Paul Hamberg, Monique M.E.M. Bos, Hans J. Braun, Jacqueline M. Stouthard, Gert A. van Deijk, Frans Erdkamp, Iris N. van der Stelt-Frissen, M. Bontenbal, Geert-Jan Creemers, Johanneke E.A. Portielje,

Clinical Breast Cancer

Breast OncologyMedicinePharmacologyClinical TrialsBreast CancerPharmacotherapyCancer TreatmentOncologyHertax TrialSequential TherapyDocetaxel Alone